JNJ vs NVS
Johnson & Johnson and Novartis AG, both Healthcare
Johnson & Johnson is the larger company at $635B against $288B. Over the past year JNJ returned +40% against +19% for NVS. The RyuScore puts NVS ahead, 75 against 68 out of 100.
| Figure | JNJ | NVS |
|---|---|---|
| Last close | $264 | $151 |
| Market cap | $635B | $288B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 40.0 | n/a |
| Dividend yield | 2.0% | n/a |
| 1-year return | +40% | +19% |
| 5-year return | +88% | +121% |
| RyuScoresector-relative, 1–10 | 68/100 | 75/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q3 2026, net income $210M. Its largest reported line is DARZALEX, 19% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.